

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p>Licensee</p> <p>1. CDL Nuclear Technologies, Inc.</p> <p>2. 6400 Brooktree Court, Suite 320 Wexford, Pennsylvania 15090</p>	<p>In accordance with the letter dated March 7, 2013,</p> <p>3. License number 37-30120-01 is amended in its entirety to read as follows:</p> <hr/> <p>4. Expiration date August 31, 2014</p> <hr/> <p>5. Docket No. 030-33422 Reference No.</p>
--	--

- | | | |
|---|---|--|
| <p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material permitted by 10 CFR 35.100</p> <p>B. Any byproduct material permitted by 10 CFR 35.200</p> <p>C. Any Byproduct material permitted by 10 CFR 31.11</p> <p>D. Americium 241</p> | <p>7. Chemical and/or physical form</p> <p>A. Any</p> <p>B. Any</p> <p>C. Prepackaged Kits</p> <p>D. Sealed Sources (Amersham Model AMC24 or AMCP4)</p> | <p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As needed</p> <p>B. As needed</p> <p>C. 5 millicuries</p> <p>D. 14 millicuries per source and 70 millicuries total</p> |
|---|---|--|

9. Authorized use:

- A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
- B. Any imaging and localization study permitted by 10 CFR 35.200.
- C. In vitro studies.
- D. Use as an anatomical marker.

CONDITIONS

- 10. Licensed material may be used or stored at the licensee's facilities located at Weirton Imaging, 3665 Pennsylvania Avenue, Weirton, West Virginia; Braxton County Memorial Hospital, 100 Hoylman Drive, Gassaway, West Virginia and may be used at temporary job sites of the licensee anywhere in the United States where the U.S. Nuclear Regulatory Commission maintains jurisdiction for regulating the use of licensed material, including areas of exclusive Federal jurisdiction within Agreement States.

If the jurisdiction status of a Federal facility within an Agreement State is unknown, the licensee should

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
37-30120-01

Docket or Reference Number
030-33422

Amendment No. 29

contact the Federal agency controlling the job site in question to determine whether the proposed job site is an area of exclusive Federal jurisdiction. Authorization for use of radioactive materials at job sites in Agreement States not under exclusive Federal jurisdiction shall be obtained from the appropriate state regulatory agency.

11. The Radiation Safety Officer for this license is Lon P. Wilson.
12. Licensed material is only authorized for use by, or under the supervision of:
- A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.
- B. The following individuals are authorized users for medical use as indicated:

Authorized Users

Material and Use

Frank S. Torok, M.D.

35.200; In vitro studies

Thomas P. Power, M.D.

35.100; 35.200; Americium 241 sealed source as an anatomical marker; In vitro studies

Ken Vesio, M.D.

35.200; In vitro studies

Shamsher Bakth, M.D.

35.200; In vitro studies

John Ward, D.O.

35.200; In vitro studies

Floyd Casady, M.D.

35.200; In vitro studies

Ramana M. Murty, M.D.

35.200; In vitro studies

John S. Gregg, M.D.

35.200

Olga Shabalov, M.D.

35.200; 35.200; In vitro studies

Glenn Miller, M.D.

35.200; In vitro studies

Douglas Schulman, M.D.

35.100; 35.200

Ajit Shah, M.D.

35.200; In vitro studies

James Zelch, M.D.

35.200; In vitro studies

Nina Wokhlu, M.D.

35.200; In vitro studies

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
37-30120-01Docket or Reference Number
030-33422

Amendment No. 29

Authorized UsersMaterial and Use

Malli Kamireddy, M.D.

35.200; In vitro studies

Thomas Komorowski, M.D.

35.200

Thomas Kavic, M.D.

35.100; 35.200

Russell F. King, II, M.D.

35.100; 35.200

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.
14. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."



**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
37-30120-01

Docket or Reference Number
030-33422

Amendment No. 29

15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

- | | | |
|----|--|---------------|
| A. | Letter (with application) dated March 24, 2004 | [ML041030076] |
| B. | Letter (with application) dated July 28, 2004 | [ML042370194] |
| C. | Letter (with application) dated March 8, 2007 | [ML070790582] |
| D. | Facsimile dated June 12, 2007
[ML071640389] | |
| E. | Letter dated September 10, 2007 | [ML072760458] |
| F. | Letter dated December 5, 2007 | [ML073460858] |
| G. | Letter dated June 25, 2009 | [ML091890898] |
| H. | Letter dated July 22, 2009 | [ML092040223] |
| I. | Letter dated March 7, 2013 | [ML13078A162] |
| J. | Letter dated April 5, 2013 | [ML13127A271] |
| K. | Contract dated February 27, 2013 contained in the e-mail dated May 7, 2013 | [ML13128A430] |

For the U.S. Nuclear Regulatory Commission

Original signed by Tara L. Weidner

Date May 17, 2013

By _____

Tara L. Weidner
Medical Branch
Division of Nuclear Materials Safety
Region I
King of Prussia, Pennsylvania 19406